Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Letters

Staff  |  Issue: August 2009  |  August 1, 2009

David,

In your recent column on Ralph Nader, “Unsafe at Any Dose?” [June 2009, p. 8], you cited rheumatology drugs pulled from the market. Frankly, I think that both Vioxx and Bextra got the bum’s rush on that one because, as we all know, over-the-counter drugs like Advil/Motrin have exactly the same level of toxicity and risk and I have heard no proposals to either pull those drugs or sue the manufacturers. Rheumatologists have often spent too much time worrying about toxicity, paralyzed in their treatment plans. This leads to use of inadequate doses of drugs (allopurinol is probably the best example of that) or inappropriate non-use (again, the endemic maltreatment of gout is really a national medical shame).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

I should also mention a horse trainer whom I met recently who takes “horse-bute” for his back pain so there is a market for phenylbutazone. It was a great drug for some patients.

Bruce N. Cronstein, MD
Paul R. Esserman Professor of Medicine
Director, Clinical and Translational Science Institute
New York University School of Medicine
New York, N.Y.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

David,

My attention was grabbed by the photo of the partial front end of a 1965 Chevrolet Corvair in The Rheumatologist [June 2009, p. 8]. Most rheumatologists are too young and won’t know Corvair; they might think you are “old school.” The color is evening orchid.

We are approximately contemporaries, so I am old enough to have purchased a new 1965 Corvair when I started medical school, and I still own it 160,000 miles later. There were seven Corvair owners in my Stanford Medical School class of 65 students, so more than 10% had Corvairs. One of them is now a master of the American College of Rheumatology.

Ralph Nader was wrong about the Corvair. Your Corvair comments would not pass the referees in a scientific publication. Sure, there were some elements of truth, but his major premise about the wheels tucking under and striking the roadway is bogus. I looked at my owner’s manual, and it is true that the tire pressures are not emphasized. There is no black box warning. Nonetheless I was aware of the tire pressure differential from the very first day. There are fans of the early (1960–1963) models, the ones identified by Nader as dangerous, but I have never ridden in or driven one. In GM’s defense, swing axle rear suspensions were usual for performance cars at that time, including VW Beetle, Mercedes-Benz “gullwing” 300SL and Porsche 356. From an automotive engineering aspect, I have to believe that the late model Corvair (1965–1969) rear suspension was superior. It is similar, and probably equal, to the contemporary Corvette independent rear suspension. The late model Corvair has been praised for both its handing and styling and was not a target of Unsafe at Any Speed.

Page: 1 2 | Single Page
Share: 

Filed under:Drug Updates Tagged with:AllopurinolDrugsMedicationrheumatology

Related Articles

    Unsafe at Any Dose?

    June 1, 2009

    Physicians must remember that all drugs have safety risks

    Drug Commercials—How Are They Still a Thing?

    July 19, 2018

    Picture this: It’s 3 o’clock in the morning. You can’t sleep. You settle in front of the television to watch a rerun of Dirty Dancing. And then it hits you: Ask your doctor. Even as your eyelids sag, some part of your primitive forebrain snaps to attention. Medical training has turned us all into multitaskers,…

    Ocular Disease Monitoring Critical to Avoid Retinal Toxicity from Hydroxychloroquine

    November 16, 2016

    Both due to its efficacy and favorable side effect profile when compared with alternative drugs for rheumatologic conditions, hydroxychloroquine is an important agent in rheumatologists’ armamentarium. However, one barrier to hydroxychloroquine use can be its effects on the eye (also see “Revised Retinopathy Screening Guidelines,”). Ocular side effects of hydroxychloroquine can include impact on the…

    Triple-Threat Rheumatologist H. Ralph Schumacher, Jr., MD, Has a Zest for Research

    January 1, 2010

    H. Ralph Schumacher, Jr., MD, has a zest for research

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences